Cytochrome P450 2C19 Genotyping CYP2C19 Clopidogrel resistance *2*3*4*10 Test
Test Name: Cytochrome P450 2C19 Genotyping CYP2C19 Clopidogrel resistance *2*3*4*10 Test
Components: EDTA Vacutainer (2ml)
Price: 1200.0 AED
Sample Condition: Peripheral blood
Report Delivery: 7 days
Method: Sanger Sequencing
Test Type: Genetics
Doctor: Gynecologist
Test Department: Pre Test Information
Cytochrome P450 2C19 Genotyping (CYP2C19) Clopidogrel resistance (*2,*3,*4,*10) can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details
Cytochrome P450 2C19 (CYP2C19) is an enzyme involved in the metabolism of various drugs, including clopidogrel. Clopidogrel is an antiplatelet medication commonly used to prevent blood clots in patients with cardiovascular diseases. However, some individuals may have a genetic variation in the CYP2C19 gene that affects the activity of the enzyme. This genetic variation can result in reduced or absent CYP2C19 enzyme function, leading to decreased metabolism of clopidogrel and reduced effectiveness of the medication. This is known as clopidogrel resistance.
There are several genetic variants of CYP2C19 that have been identified as being associated with clopidogrel resistance. These include the *2, *3, *4, and *10 alleles. These alleles are responsible for producing non-functional or reduced-function CYP2C19 enzymes. Individuals who carry one or two copies of these alleles are at an increased risk of clopidogrel resistance and may not receive the full therapeutic benefit of the medication.
Therefore, genotyping for CYP2C19 variants is recommended in certain clinical situations, such as prior to initiating clopidogrel therapy or in patients who experience recurrent cardiovascular events despite being on clopidogrel. By identifying individuals with these genetic variants, alternative antiplatelet medications or higher doses of clopidogrel can be considered to overcome the reduced effectiveness of the drug.
Test Name | Cytochrome P450 2C19 Genotyping CYP2C19 Clopidogrel resistance *2*3*4*10 Test |
---|---|
Components | EDTA Vacutainer (2ml) |
Price | 1200.0 AED |
Sample Condition | Peripheral blood |
Report Delivery | 7 days |
Method | Sanger Sequencing |
Test type | Genetics |
Doctor | Gynecologist |
Test Department: | |
Pre Test Information | Cytochrome P450 2C19 Genotyping (CYP2C19) Clopidogrel resistance (*2,*3,*4,*10) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
Test Details |
Cytochrome P450 2C19 (CYP2C19) is an enzyme involved in the metabolism of various drugs, including clopidogrel. Clopidogrel is an antiplatelet medication commonly used to prevent blood clots in patients with cardiovascular diseases. However, some individuals may have a genetic variation in the CYP2C19 gene that affects the activity of the enzyme. This genetic variation can result in reduced or absent CYP2C19 enzyme function, leading to decreased metabolism of clopidogrel and reduced effectiveness of the medication. This is known as clopidogrel resistance. There are several genetic variants of CYP2C19 that have been identified as being associated with clopidogrel resistance. These include the *2, *3, *4, and *10 alleles. These alleles are responsible for producing non-functional or reduced-function CYP2C19 enzymes. Individuals who carry one or two copies of these alleles are at an increased risk of clopidogrel resistance and may not receive the full therapeutic benefit of the medication. Therefore, genotyping for CYP2C19 variants is recommended in certain clinical situations, such as prior to initiating clopidogrel therapy or in patients who experience recurrent cardiovascular events despite being on clopidogrel. By identifying individuals with these genetic variants, alternative antiplatelet medications or higher doses of clopidogrel can be considered to overcome the reduced effectiveness of the drug. |